A randomized phase II trial of mirvetuximab soravtansine (IMGN853), in   folate receptor alpha (FR alpha)-high recurrent ovarian cancer eligible   for platinum-based chemotherapy.

Title:: A randomized phase II trial of mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FR alpha)-high recurrent ovarian cancer eligible for platinum-based chemotherapy.
Document type:: Meeting Abstract
Author(s):: Trillsch, Fabian; Schochter, Fabienne; Park-Simon, Tjoung-Won; Reuss, Alexander; Fehm, Tanja N.; Wimberger, Pauline; Bronger, Holger; Schmalfeldt, Barbara; Sehouli, Jalid; Marme, Frederik; Heitz, Florian; Mahner, Sven; Fredrich, Michaela; Barth, Stefanie; Stec, James Joseph; Method, Michael W.; Harter, Philipp
Journal title abbreviation:: J Clin Oncol
Year:: 2022
Journal volume:: 40 Suppl S
Journal issue:: 16
Print-ISSN:: 0732-183X
TUM Institution:: Klinik und Poliklinik für Frauenheilkunde
BibTeX

Occurrences: